MindRank Partners with 3SBio to Commercialize its AI-Designed Oral GLP-1 in China

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire MindRank Partners with 3SBio to Commercialize its AI-Designed Oral GLP-1 in ChinaAuthor of the article:HANGZHOU, China, Sept. 28, 2026 (GLOBE NEWSWIRE) — MindRank AI Ltd. (“MindRank”) today announced that it has entered into a strategic commercialization agreement with Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (“Mandi”) and Zhejiang Wansheng Pharmaceutical Co., Ltd. (“Wansheng”), both subsidiaries of 3SBio Inc. (01530.HK) group, for MDR-001,an AI-designed oral small-molecule GLP-1 receptor agonist in a pivotal Phase 3 trial in China for obesity and overweight. The collaboration covers mainland China, Hong Kong and Macau, with a total potential transaction value of up to RMB 1.75 billion (USD 260 million).THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThis advertisement has not loaded yet, but your article continues below.Under the agreement, Mandi and Wansheng will leverage their mature commercial capabilities to provide exclusive commercialization services for MDR-001 across all channels following regulatory approval and launch. MindRank will remain the Marketing Authorization Holder and all rights in the product’s intellectual property, and will continue to advance clinical development, registration, manufacturing, and supply of the product. MindRank will receive RMB 150 million upfront and milestone payments tied to clinical development, regulatory approval and commercialization. Upon achievement of agreed conditions, MindRank will be eligible for up to RMB 1.6 billion in additional milestone payments.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againMDR-001 is discovered and developed using MindRank’s proprietary AI-native R&D engine, Molecule Arts Platform (MAP). The drug candidate moved from initiation to Phase III in only 4.5 years, with an R&D spend of $23 million, putting a spotlight on MAP’s potential to dramatically lower drug development cost versus traditional approaches. In its phase 2b trial, mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in MDR-001 cohorts; between 34.5% and 48.1% achieved at least 10% weight loss. MDR-001 avoided the safety problems that scuttled Pfizer’s oral GLP-1 program, reporting no evidence of transaminase elevation, even among the roughly 20% of participants with pre-existing liver impairment. Except for good tolerability with no heart rate increase and only 0.8% discontinuations, the drug also improved key cardiometabolic markers like blood pressure and lipid profiles.This advertisement has not loaded yet, but your article continues below.Zhangming Niu, Founder and Chief Executive Officer of MindRank, stated: “We appreciate our partners’ confidence in MDR-001. 3SBio brings brings strong commercial capabilities and deep GLP-1 market expertise. Mandi’s hair-loss business is growing rapidly, reflecting its strengths in brand building, digital operations and channel development. Together, we will combine MindRank’s AI-driven R&D capabilities with Mandi’s commercialization strength to accelerate MDR-001 toward market and explore new AI-enabled models for commercial operations.”Jing Lou, Chairman and Chief Executive Officer of 3SBio, stated: “We are pleased to partner with MindRank. MDR-001 has generated solid clinical data, and weight management is one of Mandi’s three strategic focus areas, alongside hair and sleep management. MindRank’s AI-driven drug R&D capabilities are highly complementary to Mandi’s consumer healthcare portfolio, with MDR-001 being a particularly strong fit. Together, we look forward to advancing MDR-001 and bringing a new treatment option to people living with obesity or overweight.”This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.MindRank is a leading clinical-stage, AI-native biotechnology company dedicated to advancing innovative drug discovery and development through machine learning, reinforcement learning and first-principles calculations. Its proprietary, integrated AI platform brings together biology, structural biology, chemistry and medicine to push the boundaries of pharmaceutical innovation, develop treatments for more diseases and help more people regain their health.For more information, visit www.mindrank.ai.For BD inquiries, contact bd@mindrank.ai.For PR inquiries, contact pr@mindrank.ai.This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.